ATYR PHARMA INC (ATYR) Stock News

NASDAQ:ATYR - US0021202025 - Common Stock

5.61 USD

+0.14 (+2.56%)

Last: 9/5/2025, 8:00:01 PM

5.6 USD

-0.01 (-0.18%)

After Hours: 9/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ATYR Latest News, Press Relases and Analysis

All

Press Releases

12 hours ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 days ago - By: Benzinga - Mentions: CHRW CSIQ INTU NVDA ...

Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday

a month ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

4 months ago - By: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences

a month ago - By: Benzinga - Mentions: UPB DGNX SKYW SMCI ...

Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday

2 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

2 months ago - By: aTyr Pharma, Inc.

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

4 months ago - By: Yahoo Finance - Mentions: ATAI AQST IBRX

aTyr Pharma, Inc. (ATYR): Analysts See 485% Upside Potential

4 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

4 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

4 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

5 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

6 months ago - By: aTyr Pharma, Inc.

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

7 months ago - By: aTyr Pharma, Inc.

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

7 months ago - By: aTyr Pharma, Inc.

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference